Dissertations / Theses on the topic 'Anti-novel'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 dissertations / theses for your research on the topic 'Anti-novel.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
Gunnam, Mallikarjunareddy. "Novel anti-norovirus therapeutics." Thesis, Wichita State University, 2013. http://hdl.handle.net/10057/6818.
Full textThesis (M.S.)--Wichita State University, Fairmount College of Liberal Arts and Sciences, Dept. of Chemistry
Calhoun, McKenzie L. "Novel Anti-Diabetic Medications." Digital Commons @ East Tennessee State University, 2017. https://dc.etsu.edu/etsu-works/6885.
Full textDi, Francesco Angela Maria. "Anti-tumour properties of novel diaziridinylquinones." Thesis, University of Salford, 2001. http://usir.salford.ac.uk/26638/.
Full textAltaie, Ala. "Novel anti-oxidant properties of cobalamin." Thesis, University of Chester, 2009. http://hdl.handle.net/10034/128965.
Full textFu, Yu. "Baicalein, a novel anti-diabetic compound." Thesis, Virginia Tech, 2012. http://hdl.handle.net/10919/76854.
Full textMaster of Science
Bennett, Andrew Richard. "Novel anti-corrosion coatings on steel." Thesis, Swansea University, 2009. https://cronfa.swan.ac.uk/Record/cronfa42310.
Full textMizuhara, Tsukasa. "Development of Novel Anti-HIV Pyrimidobenzothiazine Derivatives." 京都大学 (Kyoto University), 2013. http://hdl.handle.net/2433/174545.
Full textErrey, James C. "Mechanistic studies of novel anti-tuberculosis targets." Thesis, University of East Anglia, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.398794.
Full textSeaton, Angela. "Anti-tumour activity of novel phenolic compounds." Thesis, University of Nottingham, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.324524.
Full textGorsuch, Stephen. "Synthetic approaches towards novel anti-HIV agents." Thesis, University of Reading, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.265108.
Full textMcNaughton, Emily Francis. "Novel anti-inflammatory peptides based on chemokines." Thesis, University of Bristol, 2017. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.730839.
Full textGong, Miranda Christina, and Miranda Christina Gong. "Strategies for a Novel Anti-Influenza Therapy." Thesis, The University of Arizona, 2017. http://hdl.handle.net/10150/624996.
Full textLaughridge, Carrie Butler. "Anti-Catholicism in the eighteenth century novel." Winston-Salem, NC : Wake Forest University, 2009. http://dspace.zsr.wfu.edu/jspui/handle/10339/42524.
Full textTench, Allen James. "The synthesis of novel anti viral nucleosides and novel glutamic acid analogues." Thesis, University of Reading, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.394416.
Full textLyu, Jun Fang. "Discovery of cholesterol trafficking inhibitors as novel anti-angiogenic and anti-cancer agents." Thesis, University of Macau, 2018. http://umaclib3.umac.mo/record=b3953967.
Full textHagan, Damien James. "The synthesis of novel anti-cancer acridine derivatives." Thesis, University of Nottingham, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.284428.
Full textCook, Andrew James. "Metal catalysed approaches to novel anti-cancer agents." Thesis, University of Leeds, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.411359.
Full textConner, Elaine Margaret. "Novel metal conjugates as potential anti colitic agents." Thesis, University of Strathclyde, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.249764.
Full textMullan, Patrick Joseph. "A microbiological study of novel anti-plaque agents." Thesis, University of Bristol, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.299397.
Full textRowling, Emily. "Pre-clinical evaluation of novel anti-metastatic targets." Thesis, University of Manchester, 2014. https://www.research.manchester.ac.uk/portal/en/theses/preclinical-evaluation-of-novel-antimetastatic-targets(caa9ab41-c054-4559-b575-3fd8974005a7).html.
Full textDuffy, Judith Clare. "Design of novel non-steroidal anti-inflammatory drugs." Thesis, Liverpool John Moores University, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.521744.
Full textCarson, L. "Novel anti-virulence and anti-infective strategies targeting the opportunistic bacterial pathogen, Proteus mirabilis." Thesis, Queen's University Belfast, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.546022.
Full textMenhofer, Magdalena H. "Characterization of the myxobacterial compound Chondramide as novel anti-angiogenic and anti-metastatic agent." Diss., Ludwig-Maximilians-Universität München, 2014. http://nbn-resolving.de/urn:nbn:de:bvb:19-167962.
Full textHogg, Chris. "Apelin and novel stable peptide analogues : assessing their anti-diabetic and anti-obesity potential." Thesis, Ulster University, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.734608.
Full textVerghese, Jenson. "Investigations of Novel Mechanisms of Action for Anti-Bacterial and Anti-Cancer Agent Development." VCU Scholars Compass, 2014. http://scholarscompass.vcu.edu/etd/611.
Full textSola, Lao Irene. "Novel approaches toward anti-Alzheimer and antiprotozoal drug candidates." Doctoral thesis, Universitat de Barcelona, 2016. http://hdl.handle.net/10803/399594.
Full textLa present tesis doctoral pretén el desenvolupament de nous candidats de fàrmacs anti-Alzheimer i antiprotozoaris, gràcies a l’ús de tres diferents i innovadores aproximacions: “Teràpies Multidiana”, “Reposicionament de fàrmacs” i “Validació d’una nova diana terapèutica pel tractament de Malària”. En referència a la malaltia d’Alzheimer, l’estratègia terapèutica basada en fàrmacs multidiana ha representat la base del disseny molecular i posterior síntesis de dos noves famílies estructurals proveïdes d’interaccions addicionals a aquelles establertes amb els enzims de tipus colinesteràsics, les quals s’ha demostrat que tan sols confereixen un alleujament simptomàtic de l’Alzheimer. En primer lloc, la família de compostos rhein-huprina conté una estructura híbrida constituïda per un potent inhibidor d’AChE, com és l’huprina Y, a més de per un fragment de tipus antraquinona derivat del compost rhein, que resulta en un efecte antiagregant del pèptid β-amiloide (Aβ) a part dels efectes convencionals derivats de la inhibició dual de l’enzim AChE. D’altra banda, la família d’híbrids basats en levetiracetam es composen a més d’un inhibidor d’AChE, d’una unitat relacionada amb el fàrmac antiepilèptic levetiracetam (registrat com a Keppra®), el qual reverteix l’activitat epileptiforme causada per l’agregació d’Aβ. Respecte les malalties de la Tripanosomiasis Africana i de la Malària, els fàrmacs que actualment existeixen al mercat són problemàtics, requereixen d’administració parenteral i la majoria donen lloc a molts efectes adversos, a més de produir resistències que comprometen la seva efectivitat clínica. Per aquesta raó, en el context de la present Tesis Doctoral, l’estratègia terapèutica de reposicionament de fàrmacs amb estructura d’aminoquinolina i la seva posterior optimització farmacològica ha estat usada per la ràpida recerca de noves teràpies eficaces contra la Tripanosomiasis Africana. Pel que fa a la Malària, l’enzim bifuncional de Plasmodium falciparum glucosa-6-fosfat deshidrogenasa-6-fosfogluconolactonasa (PfGluPho) ha estat validat com a diana terapèutica, gràcies a la síntesis i avaluació farmacològica d’una sèrie de compostos glucosídics amb una estructura anàloga al substrat de l’enzim, la glucosa-6-fosfat.
Yepuri, Nageshwar Rao. "The design and synthesis of novel anti-malarial agents." Access electronically, 2004. http://www.library.uow.edu.au/adt-NWU/public/adt-NWU20050330.085201/index.html.
Full textShah, Manish Bipin. "The development of novel quinols as anti-tubercular agents." Thesis, University of Nottingham, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.431861.
Full textCrapper, John Lindley. "Novel imaging and anti-tumour agents for adrenal medulla." Thesis, University of Sheffield, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.389751.
Full textMalik, Navid. "Dendrimers : evaluation as novel carriers of anti-cancer agents." Thesis, University College London (University of London), 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.313786.
Full textYousaf, Tanzeel Ahmed. "Adiponectin : a novel circulating anti-thrombotic factor in humans?" Thesis, University of Hull, 2011. http://hydra.hull.ac.uk/resources/hull:5447.
Full textGracheva, Svetlana. "Development of novel techniques for monitoring anti-oxidant thiols." Thesis, Nottingham Trent University, 2009. http://irep.ntu.ac.uk/id/eprint/182/.
Full textCeliker, Ibrahim. "The design and synthesis of novel anti-viral agents." Thesis, University of Reading, 2017. http://centaur.reading.ac.uk/72588/.
Full textRepasky, Paul J. "Novel Trisubstituted Arylidene Oxindoles with Potent Anti-Apoptotic Properties." Wright State University / OhioLINK, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=wright1310326721.
Full textFigueiredo, Joana Rita Monteiro. "Toxicity of novel anti-fouling nanomaterials in Marine organismsv." Master's thesis, Universidade de Aveiro, 2017. http://hdl.handle.net/10773/22019.
Full textBiofouling is an ecological succession of fouling communities in submerged surfaces that has extensive ecological, environmental and economic impacts worldwide when developed over man-made structures. In order to minimize this problem, biocides with anti-fouling properties are commonly used in protective coatings of submerged structures. Some decades ago, organotin compounds were used as effective anti-fouling agents, however they were completely banned in 2008 due to the toxic and biomagnification effects. As a consequence, a new generation of biocides were developed with lower toxicity and persistence in the environment when compared to organotin compounds. Recently, one of these biocides (DCOIT) was encapsulated in an engineered nanomaterial (silica mesoporous nanocapsules, SiNC-DCOIT) in order to prevent the interaction of biocides with coatings’ ingredients and control their leaching rate during the early lifetime of conventional paints, with environmental and economic benefits. The present study aimed to assess the toxicity of SiNC-DCOIT and a modified version of the engineered nanomaterial including two biocides, the SiNC-DCOIT coated with silver, to marine species and compare its toxicity with the free counterparts (empty SiNC, DCOIT and Ag). Ecotoxicity tests were carried out with eleven marine species, including bacteria (Vibrio fischeri), microalgae (Isochrysis galbana, Nannochloropsis gaditana, Phaeodactylum tricornutum), rotifers (Brachionus plicatilis), bivalves (Cerastoderma edule, Mytilus galloprovincialis), polychaetes (Hediste diversicolor), crustaceans (Artemia salina, Palaemon varians) and echinoderms (Paracentrotus lividus), following standard tests (with some adaptions in some cases). Acute or short-term chronic endpoints were used upon each species and adopted test. Globally, values of L/E/IC50 for SiNC-DCOIT, SiNC-Ag and SiNC-DCOIT-Ag were higher than the estimated values for DCOIT and silver (dissolved in solution), except for some target groups involved in the early fouling stages, proving that these alternative agents are more environmentally-friendly comparatively to free biocides. The obtained L/E/IC50 and NOEC values from the tested compounds were then used to create species sensitivity distributions together with data from literature. The HC5 and PNEC values derivated from these curves showed that the hazard of DCOIT and silver is reduced when encapsulated, highlighting these novel nanomaterials as a promising anti-fouling solution.
A bioincrustação é uma sucessão ecológica de comunidades incrustantes em superfícies submersas que tem extensos impactos ecológicos, ambientais e económicos em todo o mundo quando desenvolvida em estruturas artificiais. Para minimizar esse problema, os biocidas com propriedades anti-incrustantes são comummente utilizados em revestimentos protetores de estruturas submersas. Há algumas décadas atrás, os compostos organoestânicos eram amplamente utilizados como agentes anti-incrustantes eficazes, porém foram definitivamente banidos em 2008 devido a efeitos tóxicos e de biomagnificação reportados. Como consequência, foi desenvolvida uma nova geração de biocidas com menor toxicidade e persistência no meio ambiente em comparação com os compostos organoestânicos. Recentemente, um desses biocidas (DCOIT) foi encapsulado num nanomaterial manufaturado (nanocápsulas de sílica mesoporosas, SiNC-DCOIT), a fim de evitar a interação dos biocidas com os ingredientes dos revestimentos e controlar a sua taxa de libertação durante o início de vida das tintas convencionais, com benefícios ambientais e económicos. O presente estudo teve como objetivo avaliar os efeitos em diversas espécies marinhas do nanomaterial SiNC-DCOIT e de uma versão modificada deste, contendo dois biocidas (SiNC-DCOIT revestido com prata), e comparar a sua toxicidade com os componentes destes nanomateriais (SiNC vazias, DCOIT e Ag). Os testes de ecotoxicidade foram realizados com onze espécies marinhas, incluindo bactérias (Vibrio fischeri), microalgas (Isochrysis galbana, Nannochloropsis gaditana, Phaeodactylum tricornutum), rotíferos (Brachionus plicatilis), bivalves (Cerastoderma edule, Mytilus galloprovincialis), poliquetas (Hediste diversicolor), crustáceos (Artemia salina, Palaemon varians) e equinodermes (Paracentrotus lividus), seguindo testes padrão (com algumas adaptações em alguns casos) ou com protocolos bem definidos. Foram determinados parâmetros agudos ou crónicos de curta duração dependendo da espécie testada e do teste adotado. Globalmente, os valores de L/E/IC50 para SiNC-DCOIT, SiNC-Ag e SiNC-DCOIT-Ag foram superiores aos valores estimados para DCOIT e prata (dissolvidos em solução), com exceção de alguns grupos alvo envolvidos nos primeiros estádios de incrustação, provando assim que estes são agentes alternativos mais amigos do ambiente comparativamente aos biocidas livres. Os valores obtidos de L/E/IC50 e NOEC para os compostos testados foram depois utilizados para derivar curvas de distribuições de sensibilidade de espécies, juntamente com dados da literatura. Os valores HC5 e PNEC derivados dessas curvas mostraram que o perigo do DCOIT e da prata diminui quando encapsulados, destacando que estes nanomateriais inovadores parecem ser uma solução anti-incrustante promissora.
Soroush, Fariborz. "A Novel Microfluidic System for Screening Anti-inflammatory Therapeutics." Diss., Temple University Libraries, 2018. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/500666.
Full textPh.D.
Inflammation is a crucial physiological protective response of body to infection or injury. However, in pathological conditions such as sepsis or radiation damage, the body may exhibit a strong inflammatory response and cause organ damage. Loss of barrier function and leukocyte dysfunction plays an important role during inflammation (e.g. sepsis, radiation exposure, etc.) and induces tissue injury through release of proteases and oxygen radicals. Currently, pharmacological therapies for inflammatory conditions are supportive and there is an urgent need for specific treatments to effectively target key points in neutrophil-endothelial interaction. Our research team has developed a novel microfluidic system to study the mechanisms by which Protein Kinase C isotype delta (PKCδ) impacts neutrophil-endothelial interactions and its inhibition can protect vascular endothelial integrity and attenuate sepsis-induced tissue damage. This novel system will allow for rational design of next generation therapeutics for treating inflammation. We will utilize our novel biomimetic microfluidic assay (bMFA) to systematically delineate the mechanism by which PKCδ regulates individual steps in neutrophil recruitment to the inflamed/activated endothelium. In Specific Aim 1, we will investigate the impact of PKCδ inhibition on neutrophil interaction with endothelial cells as well as adhesion molecules expression. In Specific Aim 2, we will test the specificity of the PKCδ inhibitor in microcirculation and among different species. In Specific Aim 3, we will investigate the role of PKCδ in crosstalk between neutrophils and endothelial cells and endothelium integrity after high dose X-ray irradiation. Our findings indicate that PKCδ inhibition significantly reduces neutrophil interactions with the endothelium during acute inflammation. Our novel biomimetic microfluidic assay (bMFA) provides a rapid screening system for testing the specific response of novel therapeutics. Moreover, results indicate that in many cases the response of murine cells to inflammatory signals may be a poor predictor of response in human cells. Furthermore, our discoveries indicate a key role for PKCδ regulation of radiation-induced changes in endothelial cell barrier structure and function, expression of several key cell adhesion molecules, neutrophil-endothelial cell interaction and leukocyte migration through the endothelium. Our findings indicate that PKCδ-TAT peptide inhibitor may offer an important approach for treating inflammatory disease and we propose that PKCδ inhibition may serve as a novel medical countermeasure for treating radiation-induced vascular damage. Findings from this study will not only elucidate the mechanisms of action for this novel therapeutic but also provide a roadmap for the rational design of future therapeutics for acute inflammatory diseases. The long-term goal of this work is to establish microfluidic devices as a novel prescreening tool for screening therapeutics to allow for fast and precise prediction of response in human. This allows for efficient design of therapeutics using human cells and tissues, designing proper drug carrier, and planning possible future clinical studies.
Temple University--Theses
Molgora, Martina. "IL-1R8 : a novel checkpoint regulating anti-tumor and anti-viral activity of NK cells." Thesis, Open University, 2018. http://oro.open.ac.uk/56253/.
Full textYang, Bin Rui. "The discovery of novel ROCK inhibitors with anti-angiogenesis activity." Thesis, University of Macau, 2012. http://umaclib3.umac.mo/record=b2590323.
Full textTakeshita, Shigeru. "Genetic and physiological studies to discover novel anti-diabetic agents." 京都大学 (Kyoto University), 2016. http://hdl.handle.net/2433/215223.
Full textPuniani, Evaloni Takavaha. "Novel natural product based anti-anxiety therapy and natural insecticides." Thesis, University of Ottawa (Canada), 2004. http://hdl.handle.net/10393/29155.
Full textKinnear, D. J. "Development and characterisation of novel anti-infective endotracheal tube biomaterials." Thesis, Queen's University Belfast, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.557654.
Full textPuri, Sanyogitta. "Novel functionalized polymers for nanoparticle formulations with anti cancer drugs." Thesis, University of Nottingham, 2007. http://eprints.nottingham.ac.uk/10316/.
Full textFerguson, Jillian. "Synthesis of novel compounds for evaluation of anti-cancer activity." Thesis, University of Glasgow, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.411855.
Full textBroughton-Head, Victoria Jane. "Novel anti-inflammatory and mucolytic effects of heparin in vitro." Thesis, University of Portsmouth, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.424219.
Full textAl-Obaidi, Ahlam Ismail Ibrahim. "Examination of IKKα inhibitors as novel anti-panceatic cancer drugs." Thesis, University of Strathclyde, 2017. http://digitool.lib.strath.ac.uk:80/R/?func=dbin-jump-full&object_id=30689.
Full textCox, Jonathan A. G. "Identifying the mode of action of novel anti-tubercular drugs." Thesis, University of Birmingham, 2015. http://etheses.bham.ac.uk//id/eprint/6278/.
Full textFerguson, Elaine Lesley. "Bioresponsive polymer-phospholipase A2 conjugates as novel anti-cancer agents." Thesis, Cardiff University, 2008. http://orca.cf.ac.uk/55750/.
Full textOmoruyi, Sylvester Ifeanyi. "Investigating the anti-cancer activity of novel phenothiazines in glioblastoma." University of the Western Cape, 2018. http://hdl.handle.net/11394/6329.
Full textGlioblastoma multiforme (GBM) remains the most malignant of all primary adult brain tumours. It is a highly invasive and vascularized neoplasm with limited treatment options and very low survival rate. GBM tumours are heterogeneous in nature with cellular hierarchy and at the apex of this hierarchy are the glioblastoma stem cells, known to promote tumourigenesis and resistance to chemotherapeutic agents and tumour recurrence. Currently, the standard care for GBM involves surgical resection, radiation, and chemotherapy treatment with temozolomide. Unfortunately, median survival after treatment is still daunting and tumour relapse is very frequent. Indeed, patients with recurrent glioblastoma have less than a year survival. To address this, novel therapies need to be developed with the early introduction of promising agents into clinical trials and subsequent approval for use. Importantly, for these novel therapies to be approved for GBM, they need to be safe, effective as well as being able to penetrate the blood-brain barrier (BBB). Due to the high cost and process time for the development of new drugs, existing approved drugs are currently being repurposed for new indications and this is gaining significance in clinical pharmacology as it allows rapid delivery of useful drugs from bench to bedside. Drugs of the antipsychotic class are well known to cross the BBB due to their neuroleptic action. To this end, the aim of this study was to identify and characterize the anti-cancer activities of novel phenothiazine-derivatives belonging to the antipsychotic class of drugs in glioblastoma. To achieve this, several novel phenothiazine-derivatives were initially screened for possible anti-cancer activity in the U87 and U251 malignant GBM cells. Two lead compounds, DS00326 and DS00329, were identified and their anti-cancer activities were determined in U87 and U251 cells as well as in primary patient-derived xenograft (PDX) glioblastoma cultures. DS00326 and DS00329 significantly inhibited glioblastoma cell viability, with minimal effects observed in the non-cancerous FG0 fibroblasts. The IC50 values of DS00326 and DS00329 for U251, U87 and PDX cells ranged from 1.61 to 12.53μM. Flow cytometry analyses showed that DS00326 and DS00329 treatment led to an increase in the G1 population of cells. Additionally, DS00326 and DS00329 induced double-strand DNA breaks, which lead to activation of the canonical DNA damage response pathway. Furthermore, DS00326 and DS00329 induced apoptosis as shown by morphological markers, flow cytometry with annexin V-FITC/propidium iodide staining, as well as western blotting with an antibody to detect levels of cleaved PARP. Interestingly, treatment with DS00326 and DS00329 also induced autophagy as evident by the increase of acidic vesicular organelles in cells following staining with acridine orange as well as an increase in levels of the autophagy marker LC3-II. Autophagy was seen as a pro-death pathway in the U87 and U251 cells as inhibition of autophagy led to a reversal of cytotoxicity and consequently increased cell survival. Moreover, it was demonstrated that DS00326 and DS00329 inhibited the PI3/Akt pathway while modulating the mitogen-activated protein kinases p38, ERK1/2 and JNK signalling pathways. Importantly DS00326 and DS00329 displayed anti-cancer stem cell activities by the inhibition of neurosphere formation and regulation of stem cell markers SOX2 and GFAP in PDX cells. Together, the findings from this study suggest that DS00326 and DS00329 may be effective in the treatment of glioblastoma and provide a strong rationale for further clinical studies exploiting phenothiazines and their derivatives as treatments for glioblastoma.
2021-09-01
Rajalekshmi, Devi Sarika. "Development of Novel anti-estrogens for endocrine resistant Breast Cancer." Thesis, Virginia Tech, 2016. http://hdl.handle.net/10919/81275.
Full textMaster of Science
Ngwane, Andile H. "Development of novel anti-tuberculosis drugs from African medicinal plants." Master's thesis, University of Cape Town, 2006. http://hdl.handle.net/11427/2716.
Full text